Advances in Genetic and Molecular Approaches to Skin Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".

Deadline for manuscript submissions: 25 November 2024 | Viewed by 3299

Special Issue Editor


E-Mail Website
Guest Editor
Department of Dermatology, University Hospital Zurich, 8091 Zurich, Switzerland
Interests: skin cancers; melanoma; immunotherapy; oncolytic virotherapy; clinical research

Special Issue Information

Dear Colleagues,

Skin cancers are the most common malignancies in human. Genetic and molecular profiling has contributed to understanding the biology, improving the diagnosis and disease management in oncology and beyond. It refers to analysis of DNA, RNA, proteins and other compartments of the cell using techniques ranging from polymerase chain reaction (PCR) to multi-omics approaches. A PCR test can be run on tumor tissue to test for the BRAF V600 mutation in cutaneous melanoma, which would indicate tumor susceptibility for BRAF inhibitors; however, more advanced techniques are now used in tackling the mechanisms of resistance. Historically, genetic analysis was performed on tumor cells from metastases; however, not only detection of circulating of circulating tumor cells and DNA, but also molecular analysis is now possible. The field of genetic and molecular profiling is growing in many directions, including developing of new technologies, optimizing big-data interpretation, and understanding of clinical relevance and application.

For this Special Issue of Cancers, we welcome authors to submit original research articles or comprehensive reviews focusing on the development, research or clinical application of genetic and molecular approaches in skin cancers. We hope that such a collection of research will expand our knowledge on contemporary genetic and molecular profiling approaches and improve our understanding of their clinical implications.

Dr. Egle Ramelyte
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • genetic analysis
  • multi-omics approaches
  • skin cancer
  • mutation
  • epigenetic alteration
  • proteomics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 1348 KiB  
Article
Mutational Profiles of Cutaneous Squamous Cell Carcinomas with Different Patterns of Clinical Aggression from Head and Neck Regions
by Maria Colombino, Giuseppe Palmieri, Manuela Rodio, Matilde Tettamanzi, Silvia Rampazzo, Raffaello Margani, Emilio Trignano, Antonio Cossu, Maria Antonietta Fedeli, Giovanni Maria Fadda and Corrado Rubino
Cancers 2024, 16(11), 1956; https://doi.org/10.3390/cancers16111956 - 22 May 2024
Viewed by 1078
Abstract
Cutaneous squamous cell carcinoma is a prevalent malignancy with a rising incidence and a notably high mutational load. Exploring the genetic nuances of cSCC and investigating molecular approaches stands as a potential avenue for improving outcomes in high-risk patients. This retrospective case-control study [...] Read more.
Cutaneous squamous cell carcinoma is a prevalent malignancy with a rising incidence and a notably high mutational load. Exploring the genetic nuances of cSCC and investigating molecular approaches stands as a potential avenue for improving outcomes in high-risk patients. This retrospective case-control study involved two cohorts, one of 14 patients (the “discovery cohort”) and the other of 12 patients (the “validation cohort”), with cSCC located in the head/neck anatomical region and diagnosed at the pT2 stage. Overall, cases developed early local relapses of the disease, whereas controls never relapsed during the entire follow-up period. A next-generation sequencing (NGS) approach conducted on histological samples revealed that TP53 and CDKN2A were the most frequently mutated genes in our series. No specific mutations were identified as potential prognostic or therapeutic targets. Controls exhibited a tendency toward a higher mutational rate compared to cases. It is possible that an increased number of mutations could prompt the cSCC to expose more antigens, becoming more immunogenic and facilitating recognition by the immune system. This could enhance and sustain the immunological response, potentially preventing future recurrences. Full article
(This article belongs to the Special Issue Advances in Genetic and Molecular Approaches to Skin Cancer)
Show Figures

Figure 1

Other

Jump to: Research

12 pages, 1073 KiB  
Systematic Review
Harnessing ctDNA in Advanced Melanoma: A Promising Tool for Informed Clinical Decisions
by Rugile Pikturniene, Alvydas Cesas, Sonata Jarmalaite, Arturas Razbadauskas and Vincas Urbonas
Cancers 2024, 16(6), 1197; https://doi.org/10.3390/cancers16061197 - 18 Mar 2024
Cited by 2 | Viewed by 1789
Abstract
Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. Current monitoring methods, such as imaging scans, present limitations, prompting exploration of alternative biomarkers. This review comprehensively explores the role [...] Read more.
Cutaneous melanoma, an aggressive malignancy, has undergone significant transformation in clinical management with the introduction of immune checkpoint inhibitors (ICIs) and targeted therapies. Current monitoring methods, such as imaging scans, present limitations, prompting exploration of alternative biomarkers. This review comprehensively explores the role of circulating tumor DNA (ctDNA) in advanced melanoma, covering technical aspects, detection methods, and its prognostic and predictive value. Recent findings underscore ctDNA’s potential applications and implications in clinical practice. This review emphasizes the need for precise and dynamic biomarkers in melanoma care, positioning ctDNA as a promising blood-based tool for prognosis, treatment response, and resistance mechanisms. The technical nuances of ctDNA detection, association with melanoma mutations, and its role in guiding therapeutic decisions for immunotherapy and targeted therapy underscore its multifaceted utility, marking a paradigm shift in clinical decision-making and offering a promising trajectory for personalized and informed care in advanced melanoma. Full article
(This article belongs to the Special Issue Advances in Genetic and Molecular Approaches to Skin Cancer)
Show Figures

Figure 1

Back to TopTop